Repligen Corp

RGEN

Company Profile

  • Business description

    Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

  • Contact

    41 Seyon Street
    Building 1, Suite 100
    WalthamMA02453
    USA

    T: +1 781 250-0111

    E: [email protected]

    https://www.repligen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2025

    Employees

    1,778

Stocks News & Analysis

stocks

2 companies poised to capitalize on the rise of GLP-1 drugs

Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks

Does this bank have what it takes to compete with the big 4?

Organic growth and a recent acquisition were the focus of their investor day.
stocks

This ASX share is shrinking to greatness

A defensive opportunity for investors.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,915.0026.100.29%
CAC 408,108.436.31-0.08%
DAX 4024,046.0117.870.07%
Dow JONES (US)47,686.74268.25-0.56%
FTSE 1009,645.0921.92-0.23%
HKSE25,765.36319.72-1.23%
NASDAQ23,504.9373.20-0.31%
Nikkei 22550,581.9490.070.18%
NZX 50 Index13,486.322.330.02%
S&P 5006,838.3332.07-0.47%
S&P/ASX 2008,624.4028.800.34%
SSE Composite Index3,924.0821.270.55%

Market Movers